

CORRIGENDUM

DOI: 10.3892/mco.2020.2148

Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF- α and TGF- β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial

YASUYOSHI MIYATA, KYOHEI ARAKI, KOJIRO OHBA, TOMHIRO MASTUO, YUICHIRO NAKAMURA, TSUTOMU YUNO, YUTA MUKAI, ASATO OTSUBO, KENSUKE MITSUNARI, YASUSHI MOCHIZUKI and HIDEKI SAKAI

Mol Clin Oncol 13: 29, 2020; DOI: 10.3892/mco.2020.2099

Following the publication of this article, the authors have realized that, in the Materials and methods section, in the subsection '*Protocol*' on p. 2, the second and the final sentences of the second paragraph contained errors: The text in the second paragraph of this subsection should have been written as follows: 'RJ was procured from Yamada Agriculture Center Inc (Okayama, Japan). RJ and placebo were prepared as capsules containing **800** mg RJ and starch, respectively. They were similar in taste, smell, size, shape, and color. Capsules were administered orally **three** times per day (after breakfast, lunch, and dinner) for three months.' [NB. - it was incorrectly stated that the capsules contained 900 mg RJ, and the final sentence incorrectly stated that capsules were administered orally four times a day, including before bedtime.]

The authors regret that this error went unnoticed prior to the publication of the article, and apologize to the readership of the Journal for any inconvenience caused.



This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.